These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24396362)

  • 1. Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction.
    Namazi MH; Safi M; Vakili H; Saadat H; Karimi E; Bagheri RK
    J Tehran Heart Cent; 2013 Jul; 8(3):132-9. PubMed ID: 24396362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
    Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
    Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration.
    Gu YL; Fokkema ML; Kampinga MA; de Smet BJ; Tan ES; van den Heuvel AF; Zijlstra F
    Trials; 2009 Sep; 10():90. PubMed ID: 19785725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.
    Thiele H; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Wiemer M; Kerber S; Kleinertz K; Eitel I; Desch S; Schuler G
    Lancet; 2012 Mar; 379(9819):923-931. PubMed ID: 22357109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis.
    De Luca G; Ucci G; Cassetti E; Marino P
    J Am Coll Cardiol; 2009 May; 53(18):1668-73. PubMed ID: 19406342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy.
    Bajaj RR; Mohammad A; Hong T; Irfan A; Sharieff W; Bagnall A; Christie JA; Kutryk MJ; Chisholm RJ; Cheema AN
    J Invasive Cardiol; 2010 Aug; 22(8):347-52. PubMed ID: 20679668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials.
    Piccolo R; Eitel I; Iversen AZ; Gu YL; Dominguez-Rodriguez A; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Thiele H; Piscione F
    EuroIntervention; 2014 Jan; 9(9):1110-20. PubMed ID: 24457282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial.
    Crimi G; Pica S; Raineri C; Bramucci E; De Ferrari GM; Klersy C; Ferlini M; Marinoni B; Repetto A; Romeo M; Rosti V; Massa M; Raisaro A; Leonardi S; Rubartelli P; Oltrona Visconti L; Ferrario M
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1055-63. PubMed ID: 24156966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial.
    Eitel I; Wöhrle J; Suenkel H; Meissner J; Kerber S; Lauer B; Pauschinger M; Birkemeyer R; Axthelm C; Zimmermann R; Neuhaus P; Brosteanu O; de Waha S; Desch S; Gutberlet M; Schuler G; Thiele H
    J Am Coll Cardiol; 2013 Apr; 61(13):1447-54. PubMed ID: 23466078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of intracoronary versus intralesional injection of eptifibatide on myocardial perfusion outcomes during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction; A randomized clinical trial study.
    Ghazal A; Shemirani H; Amirpour A; Kermani-Alghoraishi M
    ARYA Atheroscler; 2019 Mar; 15(2):67-73. PubMed ID: 31440288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
    Thiele H; Wöhrle J; Neuhaus P; Brosteanu O; Sick P; Prondzinsky R; Birkemeyer R; Wiemer M; Kerber S; Schuehlen H; Kleinertz K; Axthelm C; Zimmermann R; Rittger H; Braun-Dullaeus RC; Lauer B; Burckhardt W; Ferrari M; Bergmann MW; Hambrecht R; Schuler G;
    Am Heart J; 2010 Apr; 159(4):547-54. PubMed ID: 20362711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between the Outcomes of Intracoronary and Intravenous Administration of Eptifibatide during Primary Percutaneous Coronary Intervention in Patients with Acute ST-Elevation Myocardial Infarction.
    Esfandi A; Fotouhi M; Allami A; Ebrahimi M
    J Atheroscler Thromb; 2016; 23(4):465-76. PubMed ID: 26632161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
    Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
    Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of intracoronary eptifibatide during ST-elevation myocardial infarction.
    Pinto DS; Kirtane AJ; Ruocco NA; Deibele AJ; Shui A; Buros J; Murphy SA; Gibson CM
    Am J Cardiol; 2005 Dec; 96(11):1494-7. PubMed ID: 16310428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect on myocardial perfusion and clinical outcome of intracoronary nicorandil injection prior to percutaneous coronary intervention in ST-segment elevation myocardial infarction].
    Wang ZQ; Chen MX; Liu DL; Zheng WX; Cao XZ; Chen H; Huang MF; Luo ZR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jan; 45(1):26-33. PubMed ID: 28100342
    [No Abstract]   [Full Text] [Related]  

  • 18. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study.
    Rakowski T; Zalewski J; Legutko J; Bartus S; Rzeszutko L; Dziewierz A; Sorysz D; Bryniarski L; Zmudka K; Kaluza GL; Dubiel JS; Dudek D
    Am Heart J; 2007 Mar; 153(3):360-5. PubMed ID: 17307412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction.
    Desch S; Siegemund A; Scholz U; Adam N; Eitel I; de Waha S; Fürnau G; Lurz P; Wetzel S; Schuler G; Thiele H
    Clin Res Cardiol; 2012 Feb; 101(2):117-24. PubMed ID: 22015616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI).
    Eitel I; Friedenberger J; Fuernau G; Dumjahn A; Desch S; Schuler G; Thiele H
    Clin Res Cardiol; 2011 May; 100(5):425-32. PubMed ID: 21125288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.